tetano
Editor, Senior Moderator
PLoS One
. 2023 May 10;18(5):e0285442.
doi: 10.1371/journal.pone.0285442. eCollection 2023. Protocol of a scoping review of systematic reviews and meta-analyses about COVID-19 vaccines and associated adverse events from vaccination
Shelly Melissa Pranić[SUP] 1 2 [/SUP], Lenny T Vasanthan[SUP] 3 [/SUP], Jacqueline Y Thompson[SUP] 4 [/SUP], Vinayak Mishra[SUP] 5 [/SUP], Pratyush Kumar[SUP] 6 [/SUP], Roshan Arjun Ananda[SUP] 7 [/SUP], Narges Malih[SUP] 8 9 [/SUP], Ka-King Chan[SUP] 10 [/SUP]
Affiliations
The continuous dissemination of coronavirus disease of 2019 (COVID-19) literature can inform decision-makers and the public. Since the widespread use of COVID-19 vaccines, more systematic reviews have summarized the effectiveness and reported adverse events associated with vaccination. Previous systematic and scoping reviews on COVID-19 summarized various aspects surrounding COVID-19, however, a scoping review is needed to summarize the characteristics of COVID-19 vaccines and associated adverse events reported in systematic reviews and meta-analyses to provide comprehensive evidence for informed medical decision-making. We will conduct a scoping review concerning COVID-19 vaccines and adverse events from vaccines. We will search from December 2019 to present in Epistemonikos, Campbell Library, CINAHL (Ovid), MEDLINE (Ovid), Scopus, CENTRAL (Ovid), Web of Science, WHO COVID-19 database, Joanna Briggs Institute of Excellence, and COVID-19 Evidence Reviews resource. We will include systematic reviews, meta-analyses, or both of randomized controlled trials and observational studies and exclude individual randomized controlled trials and observational studies. Abstracts and full-texts will be screened prior to selection. Investigators will independently use a calibrated quantitative and qualitative data extraction sheet and rate the quality of articles with AMSTAR, resolving disagreements to aim for good agreement (≥80%). An updated scoping review of the characteristics and safety of COVID-19 vaccines would highlight the accuracy of the evidence to inform decision-making concerning COVID-19 vaccination.
. 2023 May 10;18(5):e0285442.
doi: 10.1371/journal.pone.0285442. eCollection 2023. Protocol of a scoping review of systematic reviews and meta-analyses about COVID-19 vaccines and associated adverse events from vaccination
Shelly Melissa Pranić[SUP] 1 2 [/SUP], Lenny T Vasanthan[SUP] 3 [/SUP], Jacqueline Y Thompson[SUP] 4 [/SUP], Vinayak Mishra[SUP] 5 [/SUP], Pratyush Kumar[SUP] 6 [/SUP], Roshan Arjun Ananda[SUP] 7 [/SUP], Narges Malih[SUP] 8 9 [/SUP], Ka-King Chan[SUP] 10 [/SUP]
Affiliations
- PMID: 37163502
- DOI: 10.1371/journal.pone.0285442
The continuous dissemination of coronavirus disease of 2019 (COVID-19) literature can inform decision-makers and the public. Since the widespread use of COVID-19 vaccines, more systematic reviews have summarized the effectiveness and reported adverse events associated with vaccination. Previous systematic and scoping reviews on COVID-19 summarized various aspects surrounding COVID-19, however, a scoping review is needed to summarize the characteristics of COVID-19 vaccines and associated adverse events reported in systematic reviews and meta-analyses to provide comprehensive evidence for informed medical decision-making. We will conduct a scoping review concerning COVID-19 vaccines and adverse events from vaccines. We will search from December 2019 to present in Epistemonikos, Campbell Library, CINAHL (Ovid), MEDLINE (Ovid), Scopus, CENTRAL (Ovid), Web of Science, WHO COVID-19 database, Joanna Briggs Institute of Excellence, and COVID-19 Evidence Reviews resource. We will include systematic reviews, meta-analyses, or both of randomized controlled trials and observational studies and exclude individual randomized controlled trials and observational studies. Abstracts and full-texts will be screened prior to selection. Investigators will independently use a calibrated quantitative and qualitative data extraction sheet and rate the quality of articles with AMSTAR, resolving disagreements to aim for good agreement (≥80%). An updated scoping review of the characteristics and safety of COVID-19 vaccines would highlight the accuracy of the evidence to inform decision-making concerning COVID-19 vaccination.